{"id":"everolimus-certican","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infections (bacterial, viral, fungal)"},{"rate":"20-40","effect":"Stomatitis/mouth ulcers"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Hyperlipidemia"},{"rate":"15-25","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Pneumonitis"},{"rate":"20-30","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that suppresses cell cycle progression and reduces angiogenesis by blocking mTOR signaling. It is used primarily as an immunosuppressant in transplantation to prevent organ rejection, and also has anti-tumor activity in certain cancers by inhibiting proliferation of cancer cells dependent on mTOR pathway activation.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:54.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in heart transplant recipients"},{"name":"Prevention of organ rejection in kidney transplant recipients"},{"name":"Advanced renal cell carcinoma"},{"name":"Pancreatic neuroendocrine tumors"},{"name":"Breast cancer (hormone receptor-positive, HER2-negative)"}]},"trialDetails":[{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT03950609","phase":"PHASE2","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-30","conditions":"Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":36},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":90},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT02397083","phase":"PHASE2","title":"Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","enrollment":102},{"nctId":"NCT03008408","phase":"PHASE2","title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-18","conditions":"Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma","enrollment":90},{"nctId":"NCT03065387","phase":"PHASE1","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-31","conditions":"Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation","enrollment":93},{"nctId":"NCT00799188","phase":"PHASE3","title":"CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-10","conditions":"Cardiac Transplantation, Skin Cancer","enrollment":175},{"nctId":"NCT02321501","phase":"PHASE1","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":37},{"nctId":"NCT01582191","phase":"PHASE1","title":"Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05-14","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":151},{"nctId":"NCT02531932","phase":"PHASE2","title":"Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Amy Tiersten","startDate":"2015-12-16","conditions":"Breast Cancer","enrollment":64},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT00811590","phase":"PHASE2","title":"Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-11","conditions":"Peutz-Jeghers Syndrome","enrollment":3},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT01827384","phase":"PHASE2","title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-07","conditions":"Advanced Malignant Solid Neoplasm","enrollment":208},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT01229943","phase":"PHASE2","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-15","conditions":"Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma","enrollment":150},{"nctId":"NCT00392821","phase":"PHASE1, PHASE2","title":"Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-12","conditions":"Kidney Cancer","enrollment":78},{"nctId":"NCT00886691","phase":"PHASE2","title":"Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2010-12-27","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":150},{"nctId":"NCT03387020","phase":"PHASE1","title":"Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors","status":"COMPLETED","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2018-01-13","conditions":"CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor","enrollment":22},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02973204","phase":"","title":"Circulating Tumor Cells and Tumor DNA in HCC and NET","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-11","conditions":"Carcinoma, Hepatocellular, Neuroendocrine Tumors","enrollment":167},{"nctId":"NCT01077986","phase":"PHASE1, PHASE2","title":"Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-08","conditions":"Metastatic Pancreatic Cancer","enrollment":35},{"nctId":"NCT02812940","phase":"PHASE2","title":"Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2016-04","conditions":"Graft-versus-Host Disease","enrollment":19},{"nctId":"NCT01624766","phase":"PHASE1","title":"Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-19","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":57},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT03415750","phase":"PHASE4","title":"Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants","status":"COMPLETED","sponsor":"Edoardo Melilli","startDate":"2016-11","conditions":"Hypertrophy, Left Ventricular","enrollment":20},{"nctId":"NCT02152943","phase":"PHASE1","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-07-17","conditions":"Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive","enrollment":37},{"nctId":"NCT02283658","phase":"PHASE2","title":"Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-11-14","conditions":"Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma","enrollment":20},{"nctId":"NCT02057965","phase":"PHASE2","title":"Mesenchymal Stromal Cell Therapy in Renal Recipients","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2014-03","conditions":"Renal Transplant Rejection, Fibrosis","enrollment":70},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00823459","phase":"PHASE2","title":"Everolimus in Treating Patients With Recurrent Low-Grade Glioma","status":"COMPLETED","sponsor":"Susan Chang","startDate":"2009-01-23","conditions":"Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma","enrollment":58},{"nctId":"NCT03256864","phase":"PHASE4","title":"Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-01","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT00150046","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-12","conditions":"Heart Transplantation","enrollment":176},{"nctId":"NCT01239472","phase":"PHASE4","title":"Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant","status":"COMPLETED","sponsor":"Andre Barreto Pereira","startDate":"2011-01","conditions":"Renal Transplant Rejection, Immunosuppression","enrollment":30},{"nctId":"NCT01248403","phase":"PHASE3","title":"A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2011-10","conditions":"Advanced Gastric Cancer, Esophagogastric Junction Cancer","enrollment":300},{"nctId":"NCT02254239","phase":"PHASE1","title":"Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02-04","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":10},{"nctId":"NCT03578432","phase":"EARLY_PHASE1","title":"Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2018-05-04","conditions":"Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer","enrollment":2},{"nctId":"NCT01807767","phase":"NA","title":"Myfortic in High MELD Liver Transplantation","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2013-03","conditions":"High Model for End-Stage Liver Disease (MELD) Score","enrollment":""},{"nctId":"NCT01239342","phase":"PHASE2","title":"Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-27","conditions":"Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":43},{"nctId":"NCT02864706","phase":"PHASE4","title":"SCHEDULE Follow Up Visit 5-7 yr","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-18","conditions":"Heart Transplantation","enrollment":95},{"nctId":"NCT03228576","phase":"","title":"Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association","status":"TERMINATED","sponsor":"Poitiers University Hospital","startDate":"2017-04-14","conditions":"Kidney Transplant, Immunosuppression","enrollment":16},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT00419159","phase":"PHASE2","title":"Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Colorectal Cancer","enrollment":199},{"nctId":"NCT01198158","phase":"PHASE3","title":"Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-15","conditions":"Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":77},{"nctId":"NCT02970630","phase":"PHASE2","title":"Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-01","conditions":"Kidney Transplantation","enrollment":28},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT02328963","phase":"PHASE4","title":"Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-05-02","conditions":"Transplantation Infection, Cytomegalovirus Infection","enrollment":186},{"nctId":"NCT01150097","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-31","conditions":"Liver Transplant Recipient","enrollment":284},{"nctId":"NCT01595984","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-03","conditions":"Kidney Failure","enrollment":90},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT00331409","phase":"PHASE2","title":"Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-01","conditions":"Kidney Cancer","enrollment":23},{"nctId":"NCT00374140","phase":"PHASE2","title":"Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ahmad Tarhini","startDate":"2006-10","conditions":"Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT00935792","phase":"PHASE1, PHASE2","title":"Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-07","conditions":"Lymphocytic Leukemia","enrollment":28},{"nctId":"NCT00716573","phase":"PHASE4","title":"Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-09-16","conditions":"Cardiac Transplantation, Chronic Renal Insufficiency","enrollment":120},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01114529","phase":"PHASE3","title":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-09","conditions":"Kidney Transplantation","enrollment":828},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00651482","phase":"PHASE2","title":"Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)","status":"TERMINATED","sponsor":"Sandy Srinivas","startDate":"2008-08","conditions":"Kidney Neoplasms, Kidney (Renal Cell) Cancer","enrollment":10},{"nctId":"NCT01594268","phase":"PHASE4","title":"A Prospective, Open Label Study of CERtican in KIdney Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Kidney Transplant","enrollment":54},{"nctId":"NCT01070316","phase":"PHASE1, PHASE2","title":"Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-01","conditions":"Epilepsy, Tuberous Sclerosis Complex","enrollment":20},{"nctId":"NCT01269684","phase":"PHASE4","title":"Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT00098007","phase":"PHASE3","title":"A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-09","conditions":"Heart Transplantation","enrollment":199},{"nctId":"NCT00098241","phase":"PHASE3","title":"Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2000-06","conditions":"Kidney Transplantation","enrollment":45},{"nctId":"NCT01509560","phase":"PHASE2","title":"PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2011-11-01","conditions":"Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)","enrollment":21},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT02015728","phase":"NA","title":"Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","status":"UNKNOWN","sponsor":"Seattle Children's Hospital","startDate":"2013-12","conditions":"Recurrent Childhood Brain Tumor","enrollment":20},{"nctId":"NCT00504543","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":311},{"nctId":"NCT01653041","phase":"PHASE4","title":"Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2012-08","conditions":"Kidney Transplantation","enrollment":47},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT01204476","phase":"PHASE1","title":"Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10","conditions":"Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1","enrollment":27},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT01169701","phase":"PHASE4","title":"24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Renal Transplant","enrollment":71},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01046045","phase":"PHASE4","title":"Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-04","conditions":"Chronic Allograft Dysfunction in Renal Transplantation","enrollment":17},{"nctId":"NCT01804374","phase":"PHASE2","title":"Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06","conditions":"Metastatic Osteosarcoma, Relapsed Osteosarcoma","enrollment":38},{"nctId":"NCT01469884","phase":"PHASE4","title":"Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2011-11","conditions":"Renal Allograft, Hepatitis C","enrollment":30},{"nctId":"NCT00933374","phase":"PHASE2","title":"Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2009-07","conditions":"Bladder Cancer","enrollment":28},{"nctId":"NCT00378014","phase":"PHASE3","title":"Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-08","conditions":"Liver Transplantation","enrollment":276},{"nctId":"NCT00414440","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":431},{"nctId":"NCT02313051","phase":"PHASE2","title":"Everolimus trIal for Advanced prememopausaL Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-12","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT01283334","phase":"PHASE1, PHASE2","title":"A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-01","conditions":"Head and Neck Neoplasms, Cancer of the Head and Neck","enrollment":20},{"nctId":"NCT02254668","phase":"PHASE4","title":"Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2013-12","conditions":"Intimal Proliferation, Immunosuppression","enrollment":278},{"nctId":"NCT02036554","phase":"PHASE4","title":"Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2013-03","conditions":"Kidney; Complications, Allograft","enrollment":234},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01028092","phase":"PHASE3","title":"mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2009-03","conditions":"Renal Transplant","enrollment":327},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Certican"],"phase":"phase_3","status":"active","brandName":"Everolimus (Certican)","genericName":"Everolimus (Certican)","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Prevention of organ rejection in heart transplant recipients, Prevention of organ rejection in kidney transplant recipients, Advanced renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}